TargetBeta
AVPR2
arginine vasopressin receptor 2 · also V2R, DIR3, DIR · Arginine vasopressin and oxytocin receptors
1 program in company-led studies act on AVPR2, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Fibrosis, 1 program
- Heart Failure, 1 program
- Hyponatremia, 1 program
- Kidney Failure, Chronic, 1 program
- Polycystic Kidney, Autosomal Dominant, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 28, 2028Tolvaptan · Otsuka · phase 4 · NCT04782258
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.